FCGR2A and cancer: However, from the successes of previously reported RON-ADCs with little and reversible toxicities, it instills confidence that RON is a very safe to target molecule for cancer therapy5, and that our bispecific antibodies will likely do very well in enhancing 10G1’s cytotoxic abilities with little irreversible toxicities using current antibody engineering efforts like mutating the Fc for the CD3-bispecific antibodies to silence Fc binding to FcγR and C1q on immune cells31.